Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions Benj Gallander
LAB InternationalLAB.TOWEAK BUYNov 13, 2003
Down 13% year-to-date and 8% on a 52-week basis. Did some acquisitions in October. Revenues have been flat year on year. Not much margin. Volume can be thin. Looks like it has made a turn. Risky.
Benj GallanderUnknown
$1.21
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
TOP PICK
Changing from a clinical research organization to a product company. Good management. Very cheap.
Ed HoOwned
biotechnologypharmaceutical
